Sugi Predict

Sugi Predict / Compounds / SCHEMBL2331925

SCHEMBL2331925

SCHEMBL2331925

O=C(O)c1cn(C2CCCC2)cn1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CPB2 Q96IY4 2/20 0.45
▸ CDK5 Q00535 5/20 0.45
▸ CDK5R1 Q15078 5/20 0.45
▸ CPB1 P15086 2/20 0.42
▸ KDM2B Q8NHM5 2/20 0.42
▸ HSD17B10 Q99714 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ KDM5A P29375 3/20 0.40
▸ GSK3B P49841 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.39
▸ GLA P06280 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ HIF1A Q16665 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ KMO O15229 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28070514 0.98 CPB2 (0.44) CPB2CDK5CDK5R1CPB1KDM2B
SCHEMBL2327699 0.98 CPB2 (0.47) CPB2CDK5CDK5R1CPB1KDM2B
SCHEMBL12985681 0.96 CDK5 (0.48) CPB2CDK5CDK5R1CPB1KDM2B
Hydrochloric Acid SCHEMBL12985270 0.95 CDK5 (0.47) CPB2CDK5CDK5R1CPB1KDM2B
SCHEMBL16268981 0.93 KDM5A (0.44) CPB2CDK5CDK5R1KDM2BKDM5A
SCHEMBL27900737 0.85 CPB2 (0.49) CPB2CDK5CDK5R1KDM2BKDM5A
SCHEMBL28046409 0.85 CPB2 (0.49) CPB2CDK5CDK5R1KDM2BKDM5A
SCHEMBL2330015 0.85 GSK3B (0.43) CPB2CDK5CDK5R1KDM2BKDM5A
SCHEMBL27900736 0.85 CPB2 (0.49) CPB2CDK5CDK5R1KDM2BKDM5A
SCHEMBL13406413 0.85 KDM2B (0.49) CPB2CDK5CDK5R1CPB1KDM2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008073461-A2 ION CHANNEL MODULATORS WYETH (US) 2008-06-19 — — WO claimed
US-20250214984-A1 COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2025-07-03 — — US disclosed
EP-4146645-B1 3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES HAVING KDM5 INHIBITORY ACTIVITY AND USE THEREOF ONO PHARMACEUTICAL CO (JP) 2025-06-25 — — EP disclosed
US-12269817-B2 Compound having KDM5 inhibitory activity and pharmaceutical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2025-04-08 — — US disclosed
EP-4471027-A1 3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES HAVING KDM5 INHIBITORY ACTIVITY AND USE THEREOF ONO Pharmaceutical Co., Ltd. (JP) 2024-12-04 — — EP disclosed
US-20240376055-A1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2024-11-14 — — US disclosed
US-20240270715-A1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2024-08-15 — — US disclosed
EP-4192813-B1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2024-08-14 — — EP disclosed
CN-115461338-B 3-azabicyclo (3.1.0) hexane derivatives having KDM5 inhibitory activity and uses thereof 小野药品工业株式会社 2024-02-20 — — CN disclosed
CN-117561241-A Inhibitors of transglutaminase 策迪拉有限公司 2024-02-13 — — CN disclosed
WO-2023275336-A1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2023-01-05 — — WO disclosed
CN-115461338-A 3-azabicyclo (3.1.0) hexane derivatives having KDM5 inhibitory activity and uses thereof 小野药品工业株式会社 2022-12-09 — — CN disclosed
WO-2021223699-A1 3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES HAVING KDM5 INHIBITORY ACTIVITY AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2021-11-11 — — WO disclosed
EP-3263583-A1 IAP BIR DOMAIN BINDING COMPOUNDS Pharmascience Inc. (CA) 2018-01-03 — — EP disclosed
EP-2534170-B1 IAP BIR DOMAIN BINDING COMPOUNDS PHARMASCIENCE INC (CA) 2017-04-19 — — EP disclosed
US-9284350-B2 IAP BIR domain binding compounds PHARMASCIENCE INC. (CA) 2016-03-15 — — US disclosed
US-20130040892-A1 IAP BIR DOMAIN BINDING COMPOUNDS PHARMASCIENCE INC. (CA) 2013-02-14 — — US disclosed
EP-2534170-A1 IAP BIR DOMAIN BINDING COMPOUNDS Pharmascience Inc. (CA) 2012-12-19 — — EP disclosed
WO-2011098904-A1 IAP BIR DOMAIN BINDING COMPOUNDS AEGERA THERAPEUTICS, INC. (CA) 2011-08-18 — — WO disclosed
US-20060160794-A1 Tachykinin receptor antagonists ELI LILLY AND COMPANY 2006-07-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12269817-B2 Compound having KDM5 inhibitory activity and pharmaceutical use thereof KDM5A, KDM5B, KDM5D CPB2 4523/4885CDK5 137/4885CDK5R1 275/4885
US-20060160794-A1 Tachykinin receptor antagonists TACR1, TACR2, PROKR1 CPB2 890/4885CDK5 3876/4885CDK5R1 2056/4885
US-20130040892-A1 IAP BIR DOMAIN BINDING COMPOUNDS BIRC5, BIRC2, BIRC3 CPB2 3960/4885CDK5 2613/4885CDK5R1 1924/4885
US-20240376055-A1 INHIBITORS OF TRANSGLUTAMINASES TGM2, TGM3, TGM1 CPB2 34/4885CDK5 2492/4885CDK5R1 2627/4885
US-20250214984-A1 COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF KDM5A, KDM5B, KDM5D CPB2 4523/4885CDK5 137/4885CDK5R1 275/4885
US-20240270715-A1 INHIBITORS OF TRANSGLUTAMINASES TGM2, TGM3, TGM1 CPB2 34/4885CDK5 2492/4885CDK5R1 2627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.